Epizyme, Inc. (EPZM)
| Market Cap | 1.18B |
| Revenue (ttm) | 11.68M |
| Net Income (ttm) | -221.86M |
| Shares Out | 101.51M |
| EPS (ttm) | -2.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $11.81 |
| Previous Close | $11.73 |
| Change ($) | 0.09 |
| Change (%) | 0.72% |
| Day's Open | 11.84 |
| Day's Range | 11.48 - 11.99 |
| Day's Volume | 521,092 |
| 52-Week Range | 10.34 - 26.72 |
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme to Participate in Jefferies Virtual London Healthcare Conference
Epizyme (EPZM) reports a narrower-than-expected loss and misses sales estimates in the third quarter of 2020.
Epizyme, Inc. (EPZM) CEO Robert Bazemore on Q3 2020 Results - Earnings Call Transcript
Shares of Epizyme (NASDAQ:EPZM) remained unaffected after the company reported Q3 results.
Epizyme (EPZM) delivered earnings and revenue surprises of 9.84% and -40.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today provided ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced...
Epizyme (EPZM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Announces Two Lancet Oncology Publications on TAZVERIK® (tazemetostat) Phase 2 Data in Epithelioid Sarcoma and Follicular Lymphoma
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme (EPZM) reports a wider-than-expected loss and misses sales estimates in the second quarter of 2020.
Epizyme's (EPZM) CEO Rob Bazemore on Q2 2020 Results - Earnings Call Transcript
Epizyme (EPZM) delivered earnings and revenue surprises of -3.57% and -47.12%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme Reports Business Progress and Second Quarter 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc.
Epizyme A Buy For Tazverik And Epigenetic Platform
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.
The FDA grants approval to Epizyme's (EPZM) sNDA for lead drug,Tazverik, for two distinct follicular lymphoma indications.
Investors need to pay close attention to Epizyme (EPZM) stock based on the movements in the options market lately.
Shares of Epizyme Inc. EPZM, +4.81% were down 2.3% in premarket trading on Friday, the day after it said the Food and Drug Administration had approved Tazverik as a treatment for relapsed or r...
The label expansion for the drug significantly increases the number of patients to whom it can be prescribed.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Epizyme, Inc. Is Doing Everything Right But Its Shares Appear Fairly Priced
Epizyme (EPZM) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Epizyme (EPZM) reports a narrower-than-expected Q1 loss but misses on revenues.
Epizyme, Inc. (EPZM) CEO Rob Bazemore on Q1 2020 Results - Earnings Call Transcript
Epizyme (EPZM) delivered earnings and revenue surprises of 31.08% and -48.60%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Epizyme (NASDAQ:EPZM) were unaffected at $15.75 after the company reported Q1 results.
Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These companies scored recent drug approvals. It's worth looking into their stocks to see if they're a buy now.
Investors were looking forward to the drug company's transition to commercial operations, but the coronavirus pandemic could delay the maturation process.
Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock?
Cancer is one of the most competitive -- and lucrative -- areas for biotech investors.
On the heels of an FDA approval and with another due soon, investors may want to participate in a biotech that boasts It's
Epizyme (EPZM) reports wider-than-expected loss in the fourth quarter of 2019. Nonetheless, its sales beat estimates.
Epizyme Inc. (EPZM) CEO Rob Bazemore on Q4 2019 Results - Earnings Call Transcript
Epizyme (EPZM) delivered earnings and revenue surprises of -15.69% and 51.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.
Epizyme's NDA Accepted, And Other News: The Good, Bad And Ugly Of Biopharma
Tazemetostat is already approved to treat advanced epithelioid sarcoma; the biotech is now pursing an approval for advanced follicular lymphoma.
Epizyme (EPZM) closed at $21.78 in the latest trading session, marking a -0.5% move from the prior day.
In the latest trading session, Epizyme (EPZM) closed at $20.93, marking a -1.83% move from the previous day.
Epizyme's Tazemetostat Is Approved, And Other News: The Good, Bad, And Ugly Of Biopharma
Epizyme Has One FDA Approval Down, One More To Go In Coming Months
The biotech's FDA approval was priced in, but the company still has potential.
About EPZM
Epizyme, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma epithelioid sarcoma in the United States. It also develops Tazemetostat in combination with rituximab in patients with relapsed and refractory follicular lymphoma; R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma (DLBCL); and PARP inhibitor in patients with p... [Read more...]
| Industry Biotechnology | IPO Date May 31, 2013 |
| CEO Robert Bazemore | Employees 203 |
| Stock Exchange NASDAQ | Ticker Symbol EPZM |
Financial Performance
In 2019, Epizyme's revenue was $23.80 million, an increase of 9.68% compared to the previous year's $21.70 million. Losses were -$170.30 million, 37.7% more than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for Epizyme stock is "Buy." The 12-month stock price forecast is 23.00, which is an increase of 94.75% from the latest price.